Single User License
INR 68020
Site License
INR 136040
Corporate User License
INR 204060

Service Tax Additional

select a format
Price

Single User License
USD 1000
Site License
USD 2000
Corporate User License
USD 3000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals


  Request for Sample Report

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for July 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons To Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, July 2016 12

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, July 2016 14

2.2.1 Teva Pharma Raises USD15 Billion in Public Offering of Notes 14

2.2.2 Teva Pharma Raises USD4.4 Billion in Additional Public Offering of Notes 15

2.2.3 Celgene Enters into Agreement with Jounce Therapeutics 15

2.2.4 Galenica to Acquire Relypsa for USD1.53 Billion in Tender Offer 16

2.2.5 AstraZeneca to Enter into Co-Marketing Agreement with Aspen 17

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, July 2016 19

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, July 2016 20

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 21

3.1 Pharmaceuticals & Healthcare, Global, M&A, July 2016 21

3.1.1 Top M&A Deals in July 2016 22

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, February 2016-July 2016 23

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, July 2016 24

3.2.1 Top Equity Offering Deals in July 2016 25

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, February 2016-July 2016 26

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, July 2016 27

3.3.1 Top PE/VC Deals in July 2016 28

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, July 2016 29

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, July 2016 30

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, February 2016-July 2016 31

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, February 2016-July 2016 32

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, July 2016 33

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, February 2016-July 2016 35

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (USD m), July 2016 36

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, July 2016 37

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), February 2016-July 2016 38

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, February 2016-July 2016 40

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (USD m), February 2016-July 2016 41

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), February 2016-July 2016 42

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, July 2016 43

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, July 2016 43

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), July 2016 45

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (USD m), February 2016-July 2016 47

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (USD m), February 2016-July 2016 49

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (USD m), February 2016-July 2016 51

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (USD m), February 2016-July 2016 53

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, July 2016 54

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, July 2016 55

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, July 2016 55

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 56

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, July 2016 56

5.1.1 Oncology-Deals of the Month 57

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, July 2016 59

5.2.1 Central Nervous System-Deals of the Month 60

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, July 2016 61

5.3.1 Infectious Diseases-Deals of the Month 62

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, July 2016 64

5.4.1 Cardiovascular-Deals of the Month 65

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, July 2016 67

5.5.1 Immunology-Deals of the Month 68

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, July 2016 71

5.6.1 Gastrointestinal-Deal of the Month 72

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, July 2016 75

5.7.1 Metabolic Disorders-Deal of the Month 76

6 Deal Summary by Geography 77

6.1 Pharmaceuticals & Healthcare, North America Deals, July 2016 77

6.1.1 North America-Deals of the Month 78

6.2 Pharmaceuticals & Healthcare, Europe, Deals, July 2016 81

6.2.1 Europe-Deals of the Month 82

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, July 2016 84

6.3.1 Asia-Pacific-Deals of the Month 85

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, July 2016 87

6.4.1 Rest of the World-Deals of the Month 88

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 90

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, February 2016-July 2016 90

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, February 2016-July 2016 92

8 Further Information 94

8.1 Methodology 94

8.2 About GlobalData 95

8.3 Disclosure information 95

8.4 Disclaimer 96

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USD m), February 2016-July 2016 12

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), July 2016 19

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), July 2016 20

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (USD m), February 2016-July 2016 21

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, February 2016-July 2016 23

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), February 2016-July 2016 24

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (USD m), February 2016-July 2016 26

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (USD m), February 2016-July 2016 27

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, February 2016-July 2016 29

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), July 2016 30

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), July 2016 30

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), February 2016-July 2016 31

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), February 2016-July 2016 33

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), February 2016-July 2016 35

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), February 2016-July 2016 36

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), February 2016-July 2016 38

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2016-July 2016 40

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2016-July 2016 41

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), February 2016-July 2016 42

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), February 2016-July 2016 43

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), February 2016-July 2016 45

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), February 2016-July 2016 47

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), February 2016-July 2016 49

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, February 2016-July 2016 51

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (USD m), February 2016-July 2016 51

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (USD m), July 2016 53

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), February 2016-July 2016 56

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), February 2016-July 2016 59

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (USD m), February 2016-July 2016 61

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), February 2016-July 2016 64

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), February 2016-July 2016 67

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 71

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 75

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USD m), February 2016-July 2016 77

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USD m), February 2016-July 2016 81

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USD m), February 2016-July 2016 84

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USD m), February 2016-July 2016 87

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), February 2016-July 2016 90

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), February 2016-July 2016 92

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 13

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, July 2016 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), July 2016 20

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 22

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, July 2016 22

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, February 2016-July 2016 23

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 25

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, July 2016 25

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 26

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 28

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, July 2016 28

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, February 2016-July 2016 29

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), July 2016 31

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), February 2016-July 2016 32

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, February 2016-July 2016 32

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), February 2016-July 2016 34

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), February 2016-July 2016 35

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), February 2016-July 2016 36

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (USD m), July 2016 37

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), February 2016-July 2016 39

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2016-July 2016 41

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (USD m), February 2016-July 2016 42

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 44

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (USD m), February 2016-July 2016 46

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), February 2016-July 2016 48

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (USD m), July 2016 50

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, February 2016-July 2016 52

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), July 2016 54

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, July 2016 54

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, July 2016 55

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, July 2016 55

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 57

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 60

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 62

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 65

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 68

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 72

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 76

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 78

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 82

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 85

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USD m), February 2016-July 2016 88

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), February 2016-July 2016 91

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), February 2016-July 2016 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com